Results 161 to 170 of about 113,759 (264)

Fecal microbiota transplantation: current clinical efficacy and future prospects

Clinical and Experimental Gastroenterology, 2015
Kathryn A Bowman,1 Elizabeth K Broussard,2 Christina M Surawicz2 1Department of Medicine, 2Division of Gastroenterology, University of Washington School of Medicine, Seattle, WA, USA Abstract: Fecal microbiota transplantation (FMT) has gained mainstream
Bowman KA, Broussard EK, Surawicz CM
doaj  

Resveratrol attenuates areca nut extract‐induced chronic colitis by suppressing pyroptosis of intestinal epithelial cells via modulating cGAS/STING signaling

VIEW, Volume 7, Issue 1, February 2026.
Areca nut extract (ANE), commonly consumed in some cultures, can damage gut cells by triggering inflammation and cell death through a pathway called cGAS‐STING. This leads to the release of harmful inflammatory substances and weakens the gut barrier. Our study shows that resveratrol, a natural compound found in foods like grapes, can block this harmful
Jing Zhang, Muhammad Tufail, Yu‐Qi Huang, Can‐Hua Jiang, Ning Li   +4 more
wiley   +1 more source

Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma?

Annals of the New York Academy of Sciences, Volume 1556, Issue 1, February 2026.
Esophageal adenocarcinoma (EAC) often develops from gastroesophageal reflux disease (GERD), with Barrett's esophagus (BE) as its main precursor. While proton pump inhibitors manage GERD symptoms, their preventive role in EAC remains unclear. This review summarizes advances in diagnosing BE and evaluates anti‐reflux surgery for its potential to prevent ...
Dagmar Kollmann, Cansel Etyemez, Reza Asari, Gerd Jomrich, George Triadafilopoulos, Kenneth J. Vega, Bruno Zilberstein, Margaret J. Zhou, Qin Huang, Hiroshi Mashimo, Eun Ji Shin, John O. Clark, Sebastian F. Schoppmann   +12 more
wiley   +1 more source

Antibiotics Associated With Clostridium difficile Infection. [PDF]

Cureus, 2023
Rafey A, Jahan S, Farooq U, Akhtar F, Irshad M, Nizamuddin S, Parveen A.   +6 more
europepmc   +1 more source

Fidaxomicin versus vancomycin for Clostridium difficile infection.

New England Journal of Medicine, 2011
T. Louie, Mark A. Miller, K. Mullane, K. Weiss, A. Lentnek, Y. Golan, S. Gorbach, P. Sears, Y. Shue   +8 more
semanticscholar   +1 more source

Community-acquired Clostridium difficile infection: an increasing public health threat

Infection and Drug Resistance, 2014
Arjun Gupta, Sahil Khanna Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA Abstract: There has been a startling shift in the epidemiology of Clostridium difficile infection over the last decade worldwide, and it is now ...
Gupta A, Khanna S
doaj  

European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.

Clinical Microbiology and Infection, 2014
S. Debast, M. Bauer, E. Kuijper
semanticscholar   +1 more source

[Clostridium difficile infection].

Gaceta medica de Mexico, 2002
Clostridium difficile is an anaerobic species consisting of bacilli with large, oval, subterminal spores, normally found in intestines. It uses two toxins, which produce cytopathic changes in the intestinal mucosae, causing diarrhea. Patients can present a spectrum of disease that varies from uncomplicated antibiotic-associated diarrhea to life ...
Mónica Ivonne, Portillo-López, M Alejandro, Castellanos-Urdaibay, Elena, Cortés-Nava, Roberto, Chiprut   +3 more
openaire   +1 more source

The difficile in Clostridium difficile infection [PDF]

International Journal of Infectious Diseases, 2018
Garabet, Akoghlanian, Seetha, Lakshmi
openaire   +2 more sources

The role of toxins in Clostridium difficile infection.

FEMS Microbiology Reviews, 2017
Ramyavardhanee Chandrasekaran, Lacy Db
semanticscholar   +1 more source